Is GMRS undervalued? Our fair value estimate

GMR Solutions Inc. · Healthcare · NYQ

Our fair value estimate
USD29.35
Current share price
USD12.96
Upside to fair value
+126.5%
Screens as clearly undervalued. GMR Solutions Inc. trades 126% below the USD29.35 our model puts on the business. A fair value estimate is an argument, not a measurement: it is only as good as its growth assumption, and the market is frequently right about why something trades where it does.
Overall rating: 51/100, HoldMoat score: 24/100Data quality: high confidence (75/100 of the inputs on file)

How we got here

The estimate is computed from GMRS's reported fundamentals, with a growth assumption that is deliberately capped: small changes to an uncapped growth or terminal assumption can justify any price, and a number that can justify anything means nothing. These are the inputs the model holds for GMRS today; the exact method, and where it goes wrong, is on the methodology page.

Earnings multiple7.0x

The starting point is earnings power: what the business earns per share, and what the market currently pays for each unit of it.

Revenue growth (YoY)+6.6%

The trailing growth rate informs the growth assumption, which the model caps deliberately: uncapped growth assumptions can justify any price.

Expected EPS growth (consensus)+11.3%

Wall Street's published earnings growth forecast, used as context for the capped growth assumption, never swallowed whole.

Profit margin4.7%

Margins tell the model how much of each unit of revenue survives as profit, and how much room there is for that to erode.

Beta1.00

A volatility measure against the wider market. A jumpier share earns a larger discount for risk, which lowers the estimate.

Debt to equity10.63

Leverage haircuts the estimate: debt claims cash before shareholders do, and it turns bad years into dangerous ones.

Wall Street's number, next to ours

The mean analyst price target for GMRS is USD19.38 across 8 analysts, which implies +49.5% from the current price. Our estimate is USD29.35. They answer different questions: an analyst target is a 12-month price prediction averaged across banks; ours is a model's view of what the business is worth, with every assumption published. When they disagree, at least one of us is wrong.

Healthcare peers, by our rating

The same model, run on the highest-rated names in the same sector. A gap to fair value is only comparable when the method behind it is identical, which here it is.

Common questions

Is GMR Solutions Inc. (GMRS) undervalued?

On our model, GMRS at USD12.96 trades 126% below our fair value estimate of USD29.35, so it screens as undervalued today. That is one model's answer, not a recommendation: a fair value estimate is an argument about the future, and the market is frequently right about why something is cheap.

What is the fair value of GMRS?

Our current fair value estimate for GMR Solutions Inc. is USD29.35 per share. For comparison, the mean Wall Street analyst price target is USD19.38 across 8 analysts; that is their number, computed differently from ours. The estimate moves as prices and fundamentals move.

How is GMRS's fair value calculated?

From GMR Solutions Inc.'s reported fundamentals: earnings power, a deliberately capped growth assumption, and a discount for balance sheet and volatility risk. The full method, including its known weaknesses, is published on our methodology page, and the interactive Valuation Lab lets you change every assumption and watch the value move.

Disagree with an assumption? Good. The Valuation Lab on the GMRS app page puts every input of this model on a slider, including a reverse DCF that shows the growth the market is currently pricing in.

A fair value estimate is a model output computed from company filings and market data, refreshed daily; quotes are delayed. It is educational information, not financial advice and not a recommendation to buy or sell anything. Read the full disclaimer.